Grail Launches Galleri Multi-Cancer Test In US; Future Of Merger With Illumina Is Still Uncertain
The company launched the lab test in the US. New results from PATHFINDER trial showed an earlier version of Galleri can detect many types of cancer, including early-stage cancer that has yet to metastasize.
You may also be interested in...
Illumina announced plans to acquire Grail for about $8bn in September 2020, but the US FTC says the proposed acquisition will diminish innovation in the US market for multi-cancer testing.
The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.